How about this! The FDA's Cancer Czar Says He Can't Approve

New Post Public Reply Private Reply Replies (2) Message Board
WhyWeTrance
How about this!
The FDA's Cancer Czar Says He Can't Approve New Drugs Fast Enough
http://www.forbes.com/sites/matthewherper/201...st-enough/

Maybe more than any other person alive, Richard Pazdur, the director of the Food and Drug Administration’s Office of Oncology and Hematology Products, personifies the tension between the need to get new drugs to patients fast and the competing desire to make sure they are safe and effective first.

To his critics, he is a compassionless bureaucrat who denies cancer patients lifesaving medicines using red tape and fine print. In 2007, Richard Miller, the chief executive of a company called Pharmacyclics whose drug had been rejected, wrote a series of opinion pieces in the Wall Street Journal accusing the FDA of “stifling, rather than encouraging, investments in innovation through cumbersome and over-restrictive policies.” A New York Times profile referred to him as “the man who says no.” He received threats and was called a murderer. Another drug rejection, of the prostate cancer treatment Provenge, led 200 protestors to picket the FDA chanting “Pazdur must go!
In an interview earlier this month at the annual meeting of the American Society of Clinical Oncology, Pazdur, a greyhound-like oncologist with clear round spectacles, presented himself as anything but an obstructionist. There is a revolution on in treating tumors, he says. So far this year, seven of the 13 new drugs approved by the FDA are cancer medicines. The man himself is philosophical, and sees the need for speed. “When patients know there is an active drug, two months make a big difference, because they’re dying of a disease,” Pazdur says. “It’s like holding a glass of water in front of a person dying of thirst and saying, no, you can’t drink.”

“I think our jobs are getting easier because the drugs are better,” Pazdur says. Frequently, he isn’t even calling together the public expert panels whose approval had become a rite of passage for new cancer drugs. There’s simply nothing to ask. “We don’t have a lot of questions on drugs because they’re slam dunks. It’s not if we’re going to approve them. It’s how fast we’re going to approve them.”

This age of fast approvals is now getting a legislative boost, thanks to a provision in the FDA Safety and Innovation Act of 2012 that compels the FDA to create a new status, known as a “breakthrough” designation, for treatments for life-threatening diseases where “preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies.”

The designation joins several other FDA prizes aimed at speeding up approvals for important medicines: Priority Review, created by Congress in 1992, cuts the targeted review time for a drug from 10 months to six; Fast Track status is designed to streamline the review process for drugs that meet an unmet medical need; and Accelerated Approval allows medicines to be approved based on preliminary data pending the completion of larger studies.

A drug can get one, two, or all of these designations at once. So given that Fast Track is already supposed to speed up the review process, Priority Review to shorten it, and Accelerated Approval to make the process start earlier, what is left for the new breakthrough designation to do?

The short answer, Pazdur says, is that it catalyzes communication between a company and the FDA. Traditionally, drug reviews take place through a series of scheduled meetings. A breakthrough designation means there are more times a company can expect to be able to pick up the phone and get an answer. The designation can lead to cleared calendars, and it also means that the senior management of the FDA division becomes involved, not just the reviewers who serve on the FDA’ s front lines.

“The true measure of success is going to be how active we are in working with the companies,” Pazdur says. “If someone gets a breakthrough therapy and it’s business as usual, than the breakthrough therapy is meaningless.”

Pharmacyclics, the company whose CEO complained about Pazdur five years ago, has received three breakthrough designations for a new cancer drug, ibrutinib, that it is developing with Johnson & Johnson. Miller, the vexed chief executive, is gone. His replacement, the investor Robert Duggan, is now a billionaire as a result of the soaring value of Pharmacyclics stock. Pazdur rarely comments on the merits of drugs his division has not approved, but at an educational session at the ASCO meeting, he called the ibrutinib data impressive. He repeated that opinion in our interview.

Merck has received a breakthrough designation for a drug that targets the immune system to fight melanoma. “It’s been a significant advantage. We have immediate access to the highest level officials in the FDA oncology division and we’ve been able to obtain guidance form them about trial design in the most rapid way,” says Gary Gilliland, Merck’s oncology research head. Hal Barron, the chief medical officer at Roche, says: “We’re confident speaking with Pazdur it will increase the frequency with which we can communicate. It’s hard to imagine it won’t increase the ease of filing. We believe it will probably reduce the time.”

Mace Rothenberg, the senior vice president in charge of oncology development of Pfizer, says so far getting the indication for a Pfizer drug is helping co-ordinate not just clinical trials but also other things that can slow down a new medicine, like manufacturing and choice brand names, which FDA also regulates. He also warns: “Just as a drug can get breakthrough designation, it can lose breakthrough designation as well.”

Pazdur advises companies who plan to file for a breakthrough designation in cancer to call his office first and schedule a conference call. One reason some applications have been denied, he says, is because companies jumped the gun. “It was too early to make a decision just based on a handful of patients.”

The fact that many approvals have sped through the review process, however, does not mean that the FDA’s standards have dropped. On May 2, the agency convened an expert panel to discuss whether it should approve tivozanib, an experimental kidney cancer treatment being developed by tiny AVEO Pharmaceuticals of Cambridge, Mass. Tivozanib’s selling point was that it was supposed to have fewer side effects than the other gene-targeted cancer drugs that have transformed the treatment of kidney cancer. But at the FDA panel the agency pointed out that patients who received tivozanib died sooner than those who had received another drug, Nexavar. And Pazdur showed why he has caused so many biotech executives nightmares over the years.

“I am extremely disappointed in the sponsor’s proposed labeling for this drug,” Pazdur said during a long aside quoted in The Cancer Letter . “There is no survival curve in the proposed labeling. There is no hazard ratio— there’s difference in the means and the explanation in one or two sentences confounding by crossover.

“But if this drug is approved, one would have to have a very careful conversation with the patient about this potential negative impact on overall survival. And how would you do this? I’ve been playing this in my mind in several scenarios, and any logical patient that I could think of would say, ‘Doc, if you are so uncertain about this most important endpoint, don’t we have any other drug to use here?’”

AVEO was done. The panel voted 13 to 1 that the company had not produced sufficient efficacy data, and the FDA rejected the drug. Pazdur says that too often, companies claiming that their products are safer are just trading one side effect for another, and that, regardless, in cancer the medicines need to be as effective as what they’re replacing. (Given the toxicities of many cancer drugs, a less-toxic but equally effective medicine might have some benefit in terms of survival.)

One thing that doesn’t concern him: his critics. “There are people who have varying opinions of my performance,” he says. “But I have to do what I believe is the right thing for any given application.” Pazdur thinks hard about a lot of things. He worries that his FDA reviewers couldn’t attend the ASCO meeting where data on the drugs they will review was presented because of budget cuts mandated by the sequester (he went to receive an award for his contributions to cancer care.) He is pondering deeply how the regulation of drugs that are paired with gene tests will work. He worries about how medicines will be tested in combination with each other, and hopes maybe the National Cancer Institute will step in.

Era Of Breakthroughs

The FDA doesn’t disclose which medicines have received a breakthrough designation, but these companies have said they’ve gotten one. Originally tabulated by The Orphan Druganaut , a wonderful blog on rare disease drugs.


Sorry for the copy pasta




BioPharma Whooho 90% of my entire portfolio is BP now- It's in black & white if everyone took a look, but you guys know this...hehe

Best of luck on your Capital Gaines tax rates- Donate donate donate. I've already chosen my charities- how about you guys!?

RIVULET MEDIA INC. (RIVU) Stock Research Links

RIVU Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 53

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
SoCalGas Data Program Puts Metering Case Into Focus

Updated Category News Views 61

Buried beneath the usual utility-company polish is a pretty sensible idea: find waste before a customer gets walloped by a bill. SoCalGas says its Advanced Meter Analytics program has helped customers avoid an estimated $11 million in unnecessary natural-gas costs since 2019. That is not a number likely to move Sempra’s earnings by itself, and nobody should pretend...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 61

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 75

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 0

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Midea’s SC26 Cooling Pitch Targets AI Build Delays

Updated Category News Views 80

Heat is the uninvited partner in every AI build, and Midea is making a sensible argument that nobody gets paid for racks sitting idle while piping crews wrestle with a complicated cooling plant. At SC26 in Chicago, held November 17 through 19, the company made its North American debut for a modular prefabricated AI data-center cooling setup built around a magnetic coolant...

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 56

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 79

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 28

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading

Top 5 Most Recently Viewed Articles

Absci Corporation Shares Innovations at Key Investor Events

Updated Category News Views 144

Absci Corporation Engages Investors at Major Conferences VANCOUVER, Wash. and NEW YORK - Absci Corporation (Nasdaq: ABSI), a pioneering biotech company, is proud to announce its participation in several prestigious upcoming investor conferences. As a clinical-stage biotech, Absci is at the forefront of developing innovative therapeutics using advanced generative AI...

Continue Reading
Exciting News: Plaza Tire Service Expands to Lebanon, Missouri

Updated Category News Views 169

Expansion of Plaza Tire Service in Lebanon, Missouri Plaza Tire Service is excited to announce the opening of a new facility in Lebanon, MO. This new location enhances the brand's footprint, which already includes over 70 service centers spread across multiple states. The expansion brings accessible and reliable tire and automotive services closer to local families and...

Continue Reading
Braze's Growth Strategy: Navigating Market Challenges Ahead

Updated Category News Views 1037

Braze: A Leader in Customer Engagement Software Facing Growth Challenges Braze, Inc. (NASDAQ: BRZE), a recognized innovator in the customer engagement software sector, is currently navigating through a complex economic landscape as it strives to achieve aggressive growth targets. With its cutting-edge platform that enables businesses to analyze, segment, and interact with...

Continue Reading
Northern Venture Trust PLC Confirms New Equity Issue Details

Updated Category News Views 265

Overview of Latest Issue of Equity Northern Venture Trust PLC has taken a significant step forward with its latest equity issuance. The Company recently announced that it has allotted a total of 877,021 ordinary shares, each valued at 25p, to shareholders who opted into the Dividend Investment Scheme. The shares were made available at a subscription price of 58.3p each,...

Continue Reading
The Essential Role of Automation in Cybersecurity Management

Updated Category News Views 187

Understanding the Rising Importance of Automation in Cybersecurity As digital ecosystems continue to expand, organizations face a growing challenge in managing firewall policies across hybrid and multi-cloud environments. The increasing complexity of these systems demands innovative approaches to cybersecurity, and automation has emerged as a critical solution. By...

Continue Reading